Pfizer ups BIO ante
Executive Summary
Pfizer CEO Jeffrey Kindler is elected to the Biotechnology Industry Organization's Board of Directors, replacing Pfizer VP-Corporate Policy and Strategic Management Fred Telling. Retiring from Pfizer this year, Telling has served on the BIO board for eleven years. Pfizer has been working to expand its presence in biotech in recent years (1"The Pink Sheet" Feb. 20, 2006, p. 19)...
You may also be interested in...
Pfizer Sets Sights On Becoming Top Five Biologics Player By 2010
Pfizer is emphasizing a diversified approach, focusing on both small molecules and biotech products, as it attempts to regain investor confidence in the company's growth potential
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.